[go: up one dir, main page]

BRPI0308978A8 - fragmentos de peptídeos sintéticos ativos - Google Patents

fragmentos de peptídeos sintéticos ativos Download PDF

Info

Publication number
BRPI0308978A8
BRPI0308978A8 BRPI0308978A BR0308978A BRPI0308978A8 BR PI0308978 A8 BRPI0308978 A8 BR PI0308978A8 BR PI0308978 A BRPI0308978 A BR PI0308978A BR 0308978 A BR0308978 A BR 0308978A BR PI0308978 A8 BRPI0308978 A8 BR PI0308978A8
Authority
BR
Brazil
Prior art keywords
peptide fragments
synthetic peptide
active synthetic
amino acid
acid sequences
Prior art date
Application number
BRPI0308978A
Other languages
English (en)
Other versions
BR0308978A (pt
BRPI0308978B8 (pt
BRPI0308978B1 (pt
Inventor
John George Simpson Andrew
Jefferson Alarcon De Barrientos Frank
Sirianni Dos Santos Almeida Marília
Tendler Miriam
Magno Vilar Mônica
Katz Naftale
Charles Garrat Richard
Original Assignee
Fund Oswaldo Cruz Fiocruz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fund Oswaldo Cruz Fiocruz filed Critical Fund Oswaldo Cruz Fiocruz
Publication of BR0308978A publication Critical patent/BR0308978A/pt
Publication of BRPI0308978A8 publication Critical patent/BRPI0308978A8/pt
Publication of BRPI0308978B1 publication Critical patent/BRPI0308978B1/pt
Publication of BRPI0308978B8 publication Critical patent/BRPI0308978B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0003—Invertebrate antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43536—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms
    • C07K14/4354—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43536—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms
    • C07K14/43559—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from trematodes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"fragmentos de peptídeos sintéticos ativos". a presente invenção relaciona-se aos fragmentos peptídicos que tem uma ou mais seqüências de aminoácidos compartilhadas e/ou similares às seqüências de aminoácidos de regiões específicas da proteína de 14kda de s. mansoni (sm14) ou fabps (proteínas ligantes de ácidos graxos) relacionadas. esses fragmentos peptídicos funcionam como regiões epitópicas contínuas e descontínuas da molécula ou mimetizam sua atividade biológica. particularmente, a presente invenção relaciona-se ao método de construção de fragmentos peptídicos ativos, fragmentos peptídicos, composição imunogênica e kit diagnóstico usando fragmentos peptídicos.
BRPI0308978A 2002-04-02 2003-04-01 fragmentos de peptídeos, e, composições imunogênicas BRPI0308978B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/113,946 2002-04-02
US10/113,946 US20040006204A1 (en) 2002-04-02 2002-04-02 Synthetic active peptide fragments
PCT/BR2003/000051 WO2003082897A2 (en) 2002-04-02 2003-04-01 Synthetic active peptide fragments

Publications (4)

Publication Number Publication Date
BR0308978A BR0308978A (pt) 2006-02-21
BRPI0308978A8 true BRPI0308978A8 (pt) 2018-09-18
BRPI0308978B1 BRPI0308978B1 (pt) 2019-10-15
BRPI0308978B8 BRPI0308978B8 (pt) 2021-05-25

Family

ID=28673672

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0308978A BRPI0308978B8 (pt) 2002-04-02 2003-04-01 fragmentos de peptídeos, e, composições imunogênicas

Country Status (9)

Country Link
US (6) US20040006204A1 (pt)
EP (1) EP1495047B1 (pt)
AU (2) AU2003213900B2 (pt)
BR (1) BRPI0308978B8 (pt)
CA (1) CA2480494C (pt)
ES (1) ES2393995T3 (pt)
NZ (1) NZ536301A (pt)
WO (1) WO2003082897A2 (pt)
ZA (1) ZA200408860B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040006204A1 (en) * 2002-04-02 2004-01-08 Miriam Tendler Synthetic active peptide fragments
CA2556221C (en) * 2004-03-22 2013-12-31 Alan Marc Kleinfeld Development and use of fluorescent probes of unbound analytes
CN100383162C (zh) * 2005-05-10 2008-04-23 安徽医科大学 用于血吸虫病检测的组合检测试剂及检测方法
US8862250B2 (en) 2010-05-07 2014-10-14 Exxonmobil Research And Engineering Company Integrated expert system for identifying abnormal events in an industrial plant
KR101245004B1 (ko) 2010-10-14 2013-03-19 원광대학교산학협력단 주혈흡충증 진단에 유용한 합성 주혈흡충 특이항원 및 이를 포함하는 주혈흡충증의 검출을 위한 진단 키트
CA2985378C (en) * 2015-05-29 2023-10-10 Schlumberger Canada Limited Em-telemetry remote sensing wireless network and methods of using the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4396600A (en) * 1980-12-18 1983-08-02 Gus Gallucci Adult schistosome worm-derived antigenic substance and method of obtaining same
US5019383A (en) * 1981-01-09 1991-05-28 New York Blood Center, Inc. Fatty acid carriers for synthetic peptides
FR2601037B1 (fr) 1986-07-03 1988-10-21 Pasteur Institut Peptide presentant des proprietes antigeniques isole de la proteine 28 kd de s. mansoni et son procede d'isolement, anticorps monoclonaux reconnaissant au moins un epitope dudit peptide et application de celui-ci dans l'induction de la synthese d'anticorps neutralisants
FR2656626B1 (fr) 1989-12-29 1994-08-12 Pasteur Institut Fragment peptidique comprenant une sequence issue de la proteine 28 kda de schistosoma mansoni et compositions vaccinantes et/ou therapeutiques comprenant ledit fragment.
GB9209993D0 (en) 1992-05-08 1992-06-24 Munn Edward A Vaccines
US20040006204A1 (en) * 2002-04-02 2004-01-08 Miriam Tendler Synthetic active peptide fragments

Also Published As

Publication number Publication date
CA2480494A1 (en) 2003-10-09
EP1495047A2 (en) 2005-01-12
US20130137187A1 (en) 2013-05-30
BR0308978A (pt) 2006-02-21
BRPI0308978B8 (pt) 2021-05-25
CA2480494C (en) 2019-01-15
US10617746B2 (en) 2020-04-14
US20150064211A1 (en) 2015-03-05
BRPI0308978B1 (pt) 2019-10-15
AU2010241253B2 (en) 2013-01-10
AU2003213900B2 (en) 2010-08-05
US20040006204A1 (en) 2004-01-08
US20090312522A1 (en) 2009-12-17
ES2393995T3 (es) 2013-01-04
US20170232082A1 (en) 2017-08-17
US9670256B2 (en) 2017-06-06
US20070005255A1 (en) 2007-01-04
AU2003213900A1 (en) 2003-10-13
US8909483B2 (en) 2014-12-09
EP1495047B1 (en) 2012-08-29
WO2003082897A3 (en) 2003-12-18
NZ536301A (en) 2006-07-28
WO2003082897A2 (en) 2003-10-09
US8321143B2 (en) 2012-11-27
AU2010241253A1 (en) 2010-11-25
ZA200408860B (en) 2006-07-26

Similar Documents

Publication Publication Date Title
Lassoued et al. Bioactive peptides identified in thornback ray skin's gelatin hydrolysates by proteases from Bacillus subtilis and Bacillus amyloliquefaciens
DE60323231D1 (de) Verkürzte tau proteine
MXPA06001173A (es) Metodo analitico para la pancreatina y composiciones comparables.
CA2158058A1 (en) Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
DE60035337D1 (de) Humane Peptide/Proteine, die das Töten von Zellen, einschliesslich lymphoide Tumorzellen, herbeiführen oder bewirken
ATE506957T1 (de) Prophylaktisches/therapeutisches mittel für neurodegenerative erkrankungen
EP1978362A3 (en) Cross beta structure comprising amyloid binding proteins and methods for detection of the cross beta structure, for modulating cross beta structures fibril formation and for modulating cross beta structure-mediated toxicity
ATE306498T1 (de) Von zellen präsentierte peptide
WO2004074486A3 (en) Fusion proteins of interferon alpha muteins with improved properties
NO331277B1 (no) Farmasoytisk sammensetning omfattende polypetid/nukleinsyre for behandling av retinale degenererende sykdommer, vektor, isolert polypeptid, renset antistoff og anvendelse av polypeptid, nukleinsyre og antistoff, samt fremgangsmater og kit
BRPI0514411B8 (pt) formulação, e, método de produzir uma formulação
ES2195555T3 (es) Empleo de composiciones para proporcionar glutamina.
BRPI0308978A8 (pt) fragmentos de peptídeos sintéticos ativos
DE60102147D1 (de) Anti-gefrier proteine, deren herstellung und verwendung
ATE493966T1 (de) Mittel zur förderung der hautkollagenproduktion
DE50212280D1 (de) Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren
BR9810452A (pt) Nova combinação de medicamentos contra asma
WO1999058098A8 (en) HUMAN ANTITHROMBIN IIIs AND METHODS RELATED THERETO
ATE346091T1 (de) Neues diagnostisches reagens und kit zur erkennung von rickettsiose
Bento et al. Isolation of a polypeptide from Phoneutria nigriventer spider venom responsible for the increased vascular permeability in rabbit skin
SE9701228D0 (sv) Rekombinanta protein-C-och protein-S-varianter
WO1999055885A3 (en) Novel serine protease capable of selective cleavage of insulin-like growth factor binding protein
DE59607417D1 (de) Konjugat zur behandlung von entzündungserkrankungen
NO992531L (no) Fremgangsmåter ved fremstilling av rekombinant protein
EP1578938A4 (en) PROMOTING PEROXISOMAL CATALASE FUNCTION IN CELLS

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/10/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/10/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/04/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B15V Prolongation of time limit allowed
B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 01/04/2023